FOLH1 and neoplasm: BIND-014 is a PSMA (prostate-specific membrane antigen)-targeted nanomedicine that achieves specific binding to tumor cells or tumor-associated vasculature by modifying its nanoparticle surface with small-molecule PSMA-targeting ligands, thereby enhancing the accumulation of docetaxel at tumor sites.